{"id":"prevenar-20","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Ampicillin","action":"Avoid","effect":"Decreased efficacy of Prevnar 20"},{"drug":"Corticosteroids","action":"Monitor","effect":"Increased risk of invasive pneumococcal disease"},{"drug":"Live vaccines","action":"Avoid","effect":"Interference with immune response"},{"drug":"Other vaccines","action":"Avoid","effect":"Interference with immune response"},{"drug":"Antacids","action":"Monitor","effect":"Decreased absorption of Prevnar 20"},{"drug":"Sucralfate","action":"Monitor","effect":"Decreased absorption of Prevnar 20"},{"drug":"H2-receptor antagonists","action":"Monitor","effect":"Decreased absorption of Prevnar 20"},{"drug":"Proton pump inhibitors","action":"Monitor","effect":"Decreased absorption of Prevnar 20"}],"commonSideEffects":[],"contraindications":["Do not administer Prevnar 20 to individuals with a severe allergic reaction (e.g., anaphylaxis) to any component of Prevnar 20 or to diphtheria toxoid [see Description (11)]."],"specialPopulations":{"Pregnancy":"There are no adequate studies in women for determining infant risk when using this medication during breastfeeding.","Geriatric use":"Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of Prevnar 20™ in the elderly.","Paediatric use":"Appropriate studies have not been performed on the relationship of age to the effects of Prevnar 20™ in the pediatric population. Safety and efficacy have not been established.","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=prevenar-20","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:45:52.390174+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Prevenar-20","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:46:02.684703+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:46:00.827298+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:45:52.469556+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=prevenar-20","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:46:01.196535+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3646171/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:46:02.332255+00:00"}},"allNames":"prevenar 20","offLabel":[],"timeline":[{"date":"2021-12-01","type":"positive","_source":"Wikipedia","milestone":"CHMP adopted a positive opinion for Apexxnar","regulator":"EMA"},{"date":"2022-02-01","type":"neutral","_source":"Wikipedia","milestone":"Apexxnar authorized for medical use in the European Union","regulator":"EMA"},{"date":"2025-01-01","type":"positive","_source":"Wikipedia","milestone":"CHMP adopted a positive opinion for Capvaxive","regulator":"EMA"},{"date":"2025-03-01","type":"neutral","_source":"Wikipedia","milestone":"Capvaxive authorized for medical use in the European Union","regulator":"EMA"}],"aiSummary":"Prevenar 20 (prevenar-20) is a pneumococcal conjugate vaccine developed by Pfizer Inc. It works by conjugating purified capsular polysaccharide of pneumococcal serotypes to a carrier protein (CRM197) to improve antibody response. This vaccine is used to protect infants, young children, and geriatrics against disease caused by Streptococcus pneumoniae. Key indications include prevention of invasive disease in adults 18 years and older, 50 years and older, and 65 years and older. The vaccine has a clinical differentiation of improved antibody response compared to pneumococcal polysaccharide vaccine. Commercial significance lies in its widespread use and recommendation by the World Health Organization. Pipeline developments are not mentioned.","brandName":"Prevenar 20","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Streptococcus pneumoniae","novelty":"Best-in-class","modality":"Conjugate vaccine","drugClass":"Vaccine","explanation":"","oneSentence":"","technicalDetail":"Prevenar 20 is a conjugate vaccine that targets the capsular polysaccharide of pneumococcal serotypes, conjugating it to CRM197 to enhance antibody response. This vaccine is designed to stimulate a strong immune response against Streptococcus pneumoniae, providing protection against invasive disease. The conjugate vaccine method used in Prevenar 20 is a more effective approach than traditional polysaccharide vaccines, which can be less effective in older adults and those with certain underlying medical conditions."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_wikipedia":{"title":"Pneumococcal conjugate vaccine","extract":"Pneumococcal conjugate vaccine is a pneumococcal vaccine made with the conjugate vaccine method and used to protect infants, young children, and geriatrics against disease caused by the bacterium Streptococcus pneumoniae. It contains purified capsular polysaccharide of pneumococcal serotypes conjugated to a carrier protein (CRM197) so as to improve antibody response compared to the pneumococcal polysaccharide vaccine. The World Health Organization (WHO) recommends the use of the conjugate vaccine in routine immunizations given to children.","wiki_society_and_culture":"== Society and culture ==\n=== Legal status ===\nIn December 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Apexxnar, intended for prophylaxis against pneumococcal pneumonia and associated invasive disease. Apexxnar was authorized for medical use in the European Union in February 2022.\n\nIn January 2025, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Capvaxive, a vaccine intended for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae. Capvaxive was authorized for medical use in the European Union in March 2025.\n\n===Economics===\nPfizer reported revenue of  for the Prevnar family of vaccines (Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevnar 13 (pediatric and adult)) in 2023."},"commercial":{"annualCostUS":"","genericStatus":"Generic — off-patent","currentRevenue":"","patientPopulation":"","peakSalesEstimate":""},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=prevenar-20","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=prevenar-20","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/prevenar-20","fields":["history","overview"],"source":"Wikipedia"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:46:03.987728+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Pneumovax 23","company":"Unknown","advantage":"Pneumococcal 23-polyvalent vaccine"},{"name":"Prevnar 13","company":"Unknown","advantage":"Pneumococcal 13-valent conjugate vaccine"},{"name":"Pneumococcal 21-valent conjugate vaccine","company":"Unknown","advantage":"Pneumococcal 21-valent conjugate vaccine"},{"name":"Capvaxive","company":"Unknown","advantage":"Unknown"},{"name":"Pneumococcal 15-valent conjugate vaccine","company":"Unknown","advantage":"Pneumococcal 15-valent conjugate vaccine"}],"genericName":"prevenar-20","indications":{"approved":[{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with certain underlying medical conditions"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with certain underlying medical conditions"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with certain underlying medical conditions"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with functional or anatomic asplenia"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with functional or anatomic asplenia"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with functional or anatomic asplenia"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with HIV infection"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with HIV infection"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with HIV infection"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with chronic kidney disease"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with chronic kidney disease"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with chronic kidney disease"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with cerebrospinal fluid shunts"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with cerebrospinal fluid shunts"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with cerebrospinal fluid shunts"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with cochlear implants"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with cochlear implants"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with cochlear implants"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with heart conditions"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with heart conditions"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with heart conditions"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with lung disease"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with lung disease"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with lung disease"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with alcohol use disorder"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with alcohol use disorder"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with alcohol use disorder"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with immunocompromised conditions"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with immunocompromised conditions"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with immunocompromised conditions"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with cerebrospinal fluid leaks"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with cerebrospinal fluid leaks"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with cerebrospinal fluid leaks"},{"name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with cochlear implantation"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06622109","phase":"","title":"A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-11-25","conditions":"Pneumococcal Disease","enrollment":1100},{"nctId":"NCT06760208","phase":"","title":"A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-11-13","conditions":"Pneumococcal Immunization, Safety","enrollment":660},{"nctId":"NCT07252791","phase":"PHASE4","title":"Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-01-16","conditions":"Autoimmune Rheumatologic Disease","enrollment":114},{"nctId":"NCT07160244","phase":"PHASE3","title":"BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-25","conditions":"Healthy","enrollment":6000},{"nctId":"NCT06822907","phase":"PHASE4","title":"Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2026-01","conditions":"Acute Febrile Illness, Pneumococcal Infections","enrollment":1052},{"nctId":"NCT04460235","phase":"PHASE4","title":"Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma","status":"RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2021-09-07","conditions":"Vaccine, Streptococcus Pneumoniae, Lymphoma, Non-Hodgkin","enrollment":160},{"nctId":"NCT06986239","phase":"PHASE1","title":"Safety and Immunogenicity of PCV-LITE, a Low-dose of Pneumococcal Conjugate Vaccine With LiteVax Adjuvant","status":"NOT_YET_RECRUITING","sponsor":"LiteVax BV","startDate":"2025-07-01","conditions":"Vaccine Reaction","enrollment":80}],"_emaApprovals":[{"date":"02/03/2022","name":"Prevenar 20","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL3646171"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"notes":"","period":"2022-present","_source":"Wikipedia","companyName":"European Medicines Agency (EMA)","relationship":"Regulator"},{"notes":"","period":"2022-present","_source":"Wikipedia","companyName":"European Union","relationship":"Regulator"},{"notes":"","period":"2022-present","_source":"Wikipedia","companyName":"Pfizer (Apexxnar)","relationship":"Originator"}],"publicationCount":0,"therapeuticAreas":["Immunology"],"_revenueScrapedAt":"2026-03-31 09:33:20.331876+00","biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Vaccine","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:46:03.987728+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}